Amin Sara Adel, El Mongy Sadaka Emad Abd, Ahmed Khalid Ahmed, Barakat Ashraf Fathy, Aziem Menaisy Ahmed Abdel, Elmoneim Mahmoud Amr Abd
Department of Clinical Oncologyand Nuclear Medicine, Kafrelsheikh University,Egypt.
Department of Generaland Paediatric Surgery, Kafrelsheikh University,Egypt.
J Pak Med Assoc. 2023 Apr;73(Suppl 4)(4):S52-S55. doi: 10.47391/JPMA.EGY-S4-8.
To examine the C-X-C Motif Chemokine Receptor 1 expression in breast cancer tissues prior to neo-adjuvant chemotherapy, and its relationship to neo-adjuvant chemotherapy effectiveness and other prognostic variables.
The prospective study was conducted at Kafrelsheikh University Hospital, Egypt, from November 2018 to March 2021, and comprised patients with recent histopathologically proven breast cancer cases eligible for chemotherapy. Paraffin blocks of tumourspecimens were stained by immunohistochemicalstain using concentrating rabbit anti-human C-X-C Motif Chemokine Receptor 1 polyclonal antibody kits. C-X-C Motif Chemokine Receptor 1 expression was classified into low and high categories. Patients were followed for 2 years for treatment response, disease recurrence and mortality. Data was analysed using SPSS 25.
Of the 100 females with mean age 50.2±12.1 years, 52(52%) had their left side affected, while 48(48%) had their rightside affected. There were 52(52%) cases with mean age 49.2±12.9 years having high C-X-C Motif Chemokine Receptor 1 expresssion, while 48(48%) with mean age 51.4±11.2 years had low expression. There was a significant association between high expression and advanced tumour grade, advanced tumourstage, higher frequency of triple negative breast cancer and higher frequency of Ki-67-positive cancers (p<0.05). Patients with high C-X-C Motif Chemokine Receptor 1 expression had significantly lower frequency of complete pathological response when compared with patients with low expression (p<0.001). Patients with high expression had higher frequency of recurrence, shorter disease-free survival, higher mortality and shorter overall survival, but the difference was not significant (p>0.05). Multivariate logistic regression analysis identified triple negative hormonal status (p=0.031) and high baseline C-X-C Motif Chemokine Receptor 1 expression (p<0.001) as significant predictors of complete pathological response.
There was found to be a link between baseline C-X-C Motif Chemokine Receptor 1 expression in breast cancer tissues and pathological response to neoadjuvant therapy in breast cancer patients.
研究新辅助化疗前乳腺癌组织中C-X-C基序趋化因子受体1（CXCR1）的表达情况，及其与新辅助化疗疗效和其他预后变量的关系。
该前瞻性研究于2018年11月至2021年3月在埃及卡夫勒谢赫大学医院进行，纳入近期经组织病理学证实 eligible for chemotherapy应改为“适合化疗”的乳腺癌患者。使用浓缩兔抗人C-X-C基序趋化因子受体1多克隆抗体试剂盒，通过免疫组织化学染色对肿瘤标本石蜡块进行染色。CXCR1表达分为低表达和高表达两类。对患者进行2年的随访，观察治疗反应、疾病复发和死亡率。使用SPSS 25软件进行数据分析。
100例女性患者的平均年龄为50.2±12.1岁，其中52例（52%）左侧患病，48例（48%）右侧患病。52例（52%）平均年龄为49.2±12.9岁的患者CXCR1表达高，48例（48%）平均年龄为51.4±11.2岁的患者表达低。高表达与肿瘤分级高、肿瘤分期晚、三阴性乳腺癌频率高和Ki-67阳性癌频率高之间存在显著关联（p<0.05）。与低表达患者相比，CXCR1表达高的患者完全病理缓解的频率显著更低（p<0.001）。高表达患者的复发频率更高、无病生存期更短、死亡率更高且总生存期更短，但差异无统计学意义（p>0.05）。多因素逻辑回归分析确定三阴性激素状态（p=0.031）和基线CXCR1高表达（p<0.001）是完全病理缓解的重要预测因素。
发现乳腺癌组织中基线CXCR1表达与乳腺癌患者新辅助治疗的病理反应之间存在联系。
